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ABSTRACT
Background and objectives Presymptomatic testing 
is available for early diagnosis of hereditary autosomal 
dominant polycystic kidney disease (ADPKD). However, the 
complex ethical and psychosocial implications can make 
decision- making challenging and require an understanding 
of patients’ values, goals and priorities. This study aims 
to describe patient and caregiver beliefs and expectations 
regarding presymptomatic testing for ADPKD.
Design, setting and participants 154 participants (120 
patients and 34 caregivers) aged 18 years and over from 
eight centres in Australia, France and Korea participated in 
17 focus groups. Transcripts were analysed thematically.
Results We identiied ive themes: avoiding inancial 
disadvantage (insecurity in the inability to obtain life 
insurance, limited work opportunities, inancial burden); 
futility in uncertainty (erratic and diverse manifestations 
of disease limiting utility, taking preventive actions in 
vain, daunted by perplexity of results, unaware of risk 
of inheriting ADPKD); lacking autonomy and support 
in decisions (overwhelmed by ambiguous information, 
medicalising family planning, family pressures); seizing 
control of well- being (gaining conidence in early 
detection, allowing preparation for the future, reassurance 
in family resilience); and anticipating impact on quality of 
life (reassured by lack of symptoms, judging value of life 
with ADPKD).
Conclusions For patients with ADPKD, presymptomatic 
testing provides an opportunity to take ownership of their 
health through family planning and preventive measures. 
However, these decisions can be wrought with tensions 
and uncertainty about prognostic implications, and the 
psychosocial and inancial burden of testing. Healthcare 
professionals should focus on genetic counselling, mental 
health and providing education to patients’ families to 
support informed decision- making. Policymakers should 
consider the cost burden and risk of discrimination 
when informing government policies. Finally, patients are 
recommended to focus on self- care from an early age.
INTRODUCTION
Autosomal dominant polycystic kidney 
disease (ADPKD) is the most common 
inherited kidney disease and affects about 
10% of patients receiving kidney replace-
ment therapy.1 Early phase of ADPKD is 
often asymptomatic but the development 
of kidney cysts leads to increased kidney 
volume, reduced kidney function and even-
tually follows a relentless course towards end- 
stage kidney disease.2–8 Clinical management 
Strengths and limitations of this study
 Ź The focus groups allowed in- depth exploration of 
patients’ views on presymptomatic testing for au-
tosomal dominant polycystic kidney disease and 
helped to understand their decision- making process.
 Ź The number of participants and the diversity was 
a strength in this study, including 154 participants 
across Australia, France and Korea from both stake-
holder groups relevant to this study (caregivers and 
patients).
 Ź Research limitations are common to qualitative re-
search methodology in that the data are not gener-
alisable and are restricted to the expressed thoughts 
of participants.
 Ź We acknowledge sensitive topics may be discussed 
at the focus groups and some views may have been 
suppressed in the focus group setting.  on O
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involves pharmacological and lifestyle interventions 
to control hypertension, slow the progression of cysts, 
manage complications (kidney and extra- kidney manifes-
tations) and maintain quality of life (QoL).9–11
Diagnosis of ADPKD is usually based on family history, 
ultrasonography, CT or MRI.12 Testing, however, can facil-
itate the diagnosis of ADPKD in patients whose kidney 
phenotypes are atypical or asymptomatic, and in patients 
with unknown family history. It may also help identify 
living donors for kidney transplantation.13–15 However, 
testing has not historically been part of routine care and 
remains controversial in some countries. Typically, coun-
tries used to offer testing when a diagnosis is needed to be 
confirmed in young patients with unknown family history, 
for family planning, to determine eligibility for kidney 
donation, or when the disease presents in childhood or 
adolescence but testing in adults is overall accepted and 
encouraged.16 In some countries in Europe and Asia, 
access to asymptomatic or presymptomatic testing is very 
restricted or not available.17–20
For the scope of this paper, testing may include any 
strategy used to identify the presence of ADPKD prior 
to symptom onset (including genetic tests, blood tests, 
imaging such as ultrasound, CT, MRI, and so on).13 While 
testing for ADPKD has the potential to support early inter-
vention, patients can suffer from anxiety and depression 
from being diagnosed prior to the onset of symptoms.21–24 
There are also concerns about potential discrimination 
with employment and obtaining life insurance, and 
strains on social and familial relationships.16 The genetic 
aspect of family planning is emotionally challenging as 
patients contend with guilt and uncertainty in pursuing 
parenthood.25 Decision- making about testing is ethically 
challenging with psychosocial implications, and requires 
an understanding of the patients’ attitudes, priorities 
and perspectives of testing. The aim of this study was to 
describe patient and caregiver perspectives on the value 
and risks of testing to support the development of strate-
gies and interventions for testing for ADPKD that address 
their values and needs.
METHODS
This focus group study was conducted as part of the Stan-
dardized Outcomes in Nephrology- Polycystic Kidney 
Disease (SONG- PKD) initiative.26 This study is focused 
on perspectives of patients on testing for themselves and/
or their children. We used the Consolidated Criteria for 
Reporting Qualitative Research to report the study.27
Participant recruitment and selection
Participants were recruited across eight centres in 
Australia (n=3), France (n=4) and Korea (n=1). Partic-
ipants were eligible if they spoke English (Australia), 
French (France) or Korean (Korea), were over 18 years 
old and diagnosed with ADPKD, or a caregiver. Care-
giver refers to family member or support person and not 
their healthcare professional. We purposively sampled 
participants to capture a diverse range of demographics 
(age, gender, employment status) and clinical character-
istics (stage of chronic kidney disease, age of diagnosis, 
current treatment, comorbidities and complications). 
Recruiting clinicians identified patients with ADPKD 
who could also invite their caregivers. Participants and 
researchers had no prior relationship. Participants 
were given information packages to be able to provide 
informed consent and received reimbursement (US$25—
equivalent in local currency) for travel expenses.
Patient and public involvement
The SONG- PKD initiative26 was developed to ensure 
outcomes in trials are relevant to patients and other 
stakeholders. The SONG- PKD Steering Group comprises 
a multidisciplinary team of healthcare professionals and 
patients with PKD and was aimed to ultimately develop a 
core set of outcome domains informed by all stakeholders 
(including patients) to be reported in all trials in patients 
with ADPKD.26 Patients on the Steering Group were 
involved in the initial planning and design of the study. 
Purposive sampling was done across different centres 
and patients were able to invite any other patients who 
would be interested to participate. All participants were 
invited to be involved in the following step of SONG- PKD 
which involved completing a Delphi survey.26 Results of 
this survey will be emailed to all participants. The general 
public were not involved.
Data collection
The 2- hour focus group discussions were conducted from 
June to November 2017 until data saturation. Data satu-
ration was achieved when CL, YC and AT agreed that 
little or no new concepts were arising from subsequent 
focus groups. We developed the question guide from the 
literature and with input from the research team (online 
supplemental material and methods).25 28 29 Focus groups 
were convened in a venue external to the hospital and 
facilitated by one investigator (English—AT (researcher), 
TG (researcher), YC (academic nephrologist); French—
BS (academic nephrologist); Korean—YK (academic 
nephrologist)). Focus groups were designed with the 
intent to have a broad range of demographic and clinical 
characteristics (including patients/caregivers, age). We 
did not consider severity of symptoms a priori. We did 
not separate patients from a caregiver as they preferred 
to participate in the same group. A cofacilitator recorded 
field notes. All discussions were audio recorded and were 
transcribed.
Data analysis
All transcripts were entered into HyperRESEARCH 
(V.3.7) for analysis and coded line by line, in the orig-
inal language and then translated for investigator trian-
gulation, by CL (researcher) (English, French) and HK 
(academic nephrologist) (Korean) using thematic anal-
ysis and drawing on principles from grounded theory to 
identify concepts related to perspectives on testing for 
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ADPKD.30 From grounded theory, we conducted initial 
coding (memoing) and line- by- line coding of the data, 
used constant comparison within and across the tran-
scripts and inductively identified concepts and themes. 
In accordance with thematic analysis, we identified initial 
concepts and grouped similar concepts into themes. 
Codes were grouped by similar concepts into themes and 
subthemes which were discussed and revised with AT/
TG/YC/BS/YK who independently read the translated 
transcripts. To ensure reliable interpretation of the trans-
lated transcripts, CL and HK were available to give more 
context of the quotes. Investigator triangulation ensured 
that the analysis captured the full range and breadth of 
the data.31
RESULTS
In total, 154 participants (120 patients, 33 caregivers) 
participated in 17 focus groups across Australia, France 
and Korea. The demographics are shown in table 1. 
Participants’ age ranged from 19 to 78 years (mean 
age 54.5 years) and 67 (42%) were men. Most patients 
Table 1 Participant demographic characteristics
Characteristic
Australia 
n=85 (%)
France 
n=40 (%)
Republic of Korea 
n=29 (%)
All participants 
n=154 (%)
Participant status
  Patient 61 (71) 36 (90) 24 (83) 121 (78)
  Caregiver 24 (28) 4 (10) 5 (17) 33 (21)
  Male 35 (41) 17 (43) 12 (41) 64 (42)
Age (years)
  18–39 16 (19) 2 (5) 3 (10) 21 (14)
  40–59 34 (40) 18 (45) 20 (69) 72 (47)
  60–79 35 (41) 20 (50) 6 (21) 61 (40)
Highest level of education*
  Primary school: grade 6 4 (5) 2 (5) 1 (3) 7 (5)
  Secondary school: grade 10 18 (22) 8 (20) 2 (7) 28 (18)
  Secondary school: grade 12 7 (8) 14 (35) 5 (17) 26 (17)
  Tertiary: certiicate/diploma 25 (30) 4 (10) 0 (0) 29 (19)
  Tertiary: university degree 29 (35) 12 (30) 21 (72) 62 (41)
Employment
  Full time 21 (25) 12 (30) 17 (59) 50 (32)
  Part time or casual 17 (20) 4 (10) 3 (10) 24 16)
  Not employed 11 (13) 0 (0) 4 (14) 15 (10)
  Retired 28 (33) 19 (48) 2 (7) 49 (32)
  Other (eg, income protection insurance) 8 (9) 5 (13) 3 (10) 16 (10)
Ethnicity
  White 72 (85) 40 (100) 0 (0) 112 (73)
  Asian 7 (19) 0 (0) 29 (100) 36 (23)
  Other 6 (7) 0 (0) 0 (0) 6 (4)
CKD stage†
  Predialysis 34 (56) 20 (56) 20 (83) 74 (61)
  Dialysis 11 (18) 2 (6) 3 (13) 16 (13)
  Transplantation 16 (26) 14 (39) 1 (4) 31 (26)
Age at diagnosis*† (years)
  0–20 10 (16) 6 (17) 3 (13) 19 (16)
  21–40 35 (57) 21 (58) 14 (58) 70 (58)
  41–60 13 (21) 7 (19) 6 (25) 26 (21)
  >60 3 (5) 2 (6) 1 (4) 6 (5)
*Missing data from two participants.
†Patient only (n=61; n=31; n=24).
CKD, chronic kidney disease.
 on O
ctober 15, 2020 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-038005 on 10 O
ctober 2020. D
ow
nloaded from
 
4 Logeman C, et al. BMJ Open 2020;10:e038005. doi:10.1136/bmjopen-2020-038005
Open access 
were diagnosed between the ages of 21 and 40 years 
and the majority of patients were predialysis (n=76, 
61%), followed by transplant recipients (n=31, 26%) 
and those on dialysis (n=19, 13%). The majority of care-
givers defined themselves as the spouse or partner of 
the patient (n=24, 71%), but also included child (n=2, 
6%), daughter- in- law (n=1, 3%), parent (n=4, 12%) and 
sibling (n=1, 3%). Reasons for declining to participate 
included having other commitments and being too 
unwell to participate.
Five themes were identified with both patients and care-
givers contributing to the concept unless otherwise stated: 
avoiding financial disadvantage, futility in uncertainty, 
lacking autonomy and support in making decisions, 
seizing control of well- being and anticipating impact on 
QoL. Subthemes are described in the following section. 
Illustrative quotations for each theme are provided in 
table 2. The conceptual links among themes are depicted 
in figure 1.
Avoiding inancial disadvantage
Insecurity in the inability to obtain life insurance
Some participants (specifically caregivers) were 
concerned about patients being labelled as ‘high risk’ 
when assessed for life insurance and expected they would 
pay higher premiums, be unable to obtain insurance or 
be ‘dropped’ by their insurance provider. They suspected 
they would be unfairly penalised for a disease that may not 
manifest. For this reason, some did not disclose ADPKD 
or avoided confirmatory tests—‘Don’t get it confirmed, just 
live your life as long as you can without being diagnosed’ (care-
giver, France). Parents worried that limited insurance 
would restrict their children from travelling and from 
attending school camps.
Limiting work opportunities
Some patients feared discrimination from employers 
who could deny or dismiss them because of a diagnosis. 
Some worried that the disease would impair their phys-
ical ability to perform at work. Parents considered how 
the risks of early diagnosis through testing may jeopardise 
work opportunities for their children—‘[my] doctor advised 
me to organize a genetic test for [my son] … but then I think 
if his test result comes back positive … this may have a nega-
tive impact on his ability to work in future’ (Australia). Some 
refused tests and avoided disclosing their medical history 
to protect employment prospects.
Financial burden
Some presymptomatic participants wanted to undergo 
testing for ADPKD, but the cost was prohibitive, partic-
ularly for participants in Korea—‘Genetic testing raises 
concerns about associated cost…. spending a lot of money in 
advance is a burden’ (Korea). Some believed that a history 
of ADPKD warranted reimbursement from the govern-
ment to improve equity of access to testing.
Futility in uncertainty
Erratic and diverse manifestations of disease limiting utility
The symptoms of ADPKD were regarded as unpredictable, 
such that a diagnosis would not provide useful informa-
tion about symptom burden and prognosis. Patients and 
caregivers believed it was unnecessary to be concerned 
until symptoms become apparent—‘[confirmatory testing] 
was a big call to make for something that could never ever actu-
ally develop’ (Australia).
Taking preventive actions in vain
Participants who had been diagnosed through screening 
felt frustrated when attempts to minimise disease progres-
sion (eg, with antihypertensive medications or smoking 
cessation) proved futile. Some felt helpless and perceived 
that testing prior to experiencing symptoms was useless 
since they were powerless to change the unpredictable 
course—‘There’s no benefit to knowing early. There is nothing 
they can do to change the outcome, it’s going to happen in its own 
time’ (Australia).
Daunted by perplexity of results
Some parents worried that their child would be over-
whelmed in trying to comprehend or interpret the 
results from testing and that it would create ‘a sword of 
Damocles over [their] head causing worry, anxiety, depression 
and even posttraumatic stress disorder’ (France).
Unaware of risk of inheriting PKD
The threat of transmitting the disease to their chil-
dren caused decisional conflict about testing. Some 
felt they would be more empowered by knowing the 
results—‘Knowing that you’ve got a possibility of a child 
having a disease is good, it can help you with other deci-
sions’ (Australia). Others struggled with the uncer-
tainty of the impact of tests on decisions about family 
planning—‘probably the biggest impact in my life at the 
moment is whether or not I want to consider passing on the 
PKD gene’ (Australia). For parents who were diagnosed 
after having children, they believed that the diagnosis 
would not have impacted their decisions and were 
aware of options such as preimplantation genetic diag-
nosis—‘Genetically if there was some way of knowing that 
I was going to pass it on would I take that, or would I just 
go ahead and have the child? […] I would have the child’ 
(Australia).
Lacking support and autonomy in decisions
Overwhelmed by ambiguous information
Participants felt ‘completely in the dark’ about testing. They 
struggled with conflicting opinions, such as what age 
to get screened, and some felt misled by clinicians—‘I 
remember the specialist [saying to mum], “girls don’t get polycystic 
kidney disease so you’re fine having two girls,” so my sister and 
I lived in oblivion until I was 42’ (Australia). Some thought 
that clinicians did not provide adequate genetic coun-
selling. In Australia, some were unaware that a genetic 
test was available and felt they should be informed. They 
searched for information on the internet and asked other 
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Table 2 Selected illustrative quotations
Theme Illustrative quotations
Avoiding inancial disadvantage
Insecurity in the inability to obtain 
life insurance
I asked many years ago whether I could have testing done on my children and I was told yes, 
but it’s not advised, because if it was proven that either of them were likely to get polycystic 
kidneys, they would never be able to go on a school camp, and they would never get life 
insurance. (Australia)
He’s 21 now and I’m pretty certain he has it and I say to him, ‘Whatever you do don't get it 
conirmed, just live your life as long as you can without being diagnosed, without getting it there 
in writing that you’ve got it,’ because superannuation, life insurance, job prospects, all these 
sorts of things that come up that are going to be detrimental or change his life in some way. 
(Australia)
I actually tried to get some extra life insurance cover through superannuation and they said 
‘yeah, polycystic kidneys, nope can’t do it’ so I got [doctor] to write a detailed letter about my 
renal function, and he reckons I’m going to be good for another 20 years, and they still wouldn’t 
insure me. (Australia)
If you are not insured in health expenses insurance, you can be reimbursed later on but if you 
are diagnosed with PKD in your teens then you can’t get insured. (Korea)
Limited work opportunities Even applying for jobs now, they ask you about your medical history. If you don’t know, you 
can’t write it down. (Australia)
When I went for jobs, my job provider turned around and said, ‘You have to tell them anything 
that will affect your job.’ (Australia)
My oldest son is in high school and the doctor advised me to organize genetic test for him 
before he enters army. I think if his test results come back positive and he is unable to attend 
army that may have a negative impact on his ability to work in future. I worry that it will place 
him in disadvantaged position. (Korea)
Financial burden My nephew and his wife were pregnant, and she was going to get a test to see whether his 
daughter had polycystic kidneys. But the cost was huge, so he didn’t do it. (Australia)
Genetic testing raises concerns about associated costs. There is added cost when you don’t 
know about diagnosis. Spending a lot of money in advance is a burden. (Korea)
My family decided to undergo genetic testing with government support. It’s quite expensive for a 
whole family to do. It would be better if these aspects can be improved to reduce the burden on 
family. (Korea)
Futility in uncertainty
Erratic and diverse manifestation of 
disease limiting utility
There are just so many variables in it, and there are plenty of people that die, and didn’t even 
know that they had it, they discovered it in autopsy. I just thought, [genetic testing] was a big call 
to make for something that could never ever actually develop. (Australia)
You don’t assume that another person will get those same symptoms… everyone will be 
different, some similar but not the same. (Australia)
Some people can go all through and live to old age and not know. It’s just a slower growing cyst, 
or a different form of PKD. There are some babies that are born with PKD that’s not conducive 
to life. (Australia)
There are no two people the same in terms of what works or what, why it started or how quickly 
it declines. (Australia)
Taking preventive actions in vain There’s no beneit to knowing early. There is nothing they can do to change the outcome; it’s 
going to happen in its own time at this stage anyhow, so why spoil that young person’s life? 
(Australia)
No matter what you’re going to go through the process anyway, if you’ve got it. (Australia)
I thought of this [genetic test] very negatively. There is no effective treatment, so why you need 
to know early. Knowing early without treatment means that you are mentally suffering… you 
have to live in pain as soon as you know. (Korea)
To tell us information when there’s no possibility to make things better, is just giving anxiety for 
nothing. (France)
Daunted by perplexity of results Everyone is not equal before the disease. To teach a young person that he has a sword of 
Damocles over his head, that he will be dialyzed, maybe grafted may psychologically damage 
him. (France)
He just didn’t cope [with his possible diagnosis]. In fact, I even wondered if he was going to do 
something ghastly to himself. (Australia)
I would just rather go through life not having to have that cloud over me at any point. So, if I was 
in my twenties and somebody said, ‘Here you can do genetic testing and it will show you've got 
this,’ I wouldn't want to. I just don't want to have that limiting my life at that point. (Australia)
I have an 18- year- old son, when I broach the subject of him getting tested, what is it going to 
achieve? It’s only going to cause more stress. (Australia)
Continued
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Theme Illustrative quotations
Unaware of risk of inheriting ADPKD Fertility and the genetics of PKD really fascinate me and impact me a lot and that’s probably the 
biggest impact in my life at the moment is whether or not I want to consider passing on the PKD 
gene, or to adopt, or if I want to terminate if I ind out they do have it. (Australia)
Knowing at some stage that you've got a possibility of a child having a disease is good because 
then it can help you with other decisions. (Australia)
I'm only 25, I do not have children, and it’s true that this is a question I'm asking myself today. 
What do I do? Have children? Naturally or do I ask to go into a process of assisted reproduction 
to try to remove that gene. (France)
I cried a lot blaming [my mother in law] why my husband had to suffer from this genetically 
inherited disease…. My biggest wish is that this does not affect my children. (Korea)
Lacking autonomy and support in decisions
Overwhelmed by ambiguous 
information
He [doctor] didn’t know what to say. Screen or don’t screen. (France)
I didn’t have enough information on that, so I tried to search the internet. (France)
No one’s ever brought [genetic counseling] up to me, it’s always been, ‘Oh, this is what you’re 
looking forward to, this is what we have to do to your mother,’ it’s never been on the fertility part 
of it at all and I actually had to go to a fertility doctor to help me. (Australia)
[Genetic testing] is rarely offered to us. (France)
Medicalising family planning I was a young woman, and [the doctor] said when you get to the point of having children, we 
can certainly test your fetus to see if it has polycystic kidney disease, and then you could 
terminate if it did. And I didn’t go back to him, ‘cause I didn’t like that. (Australia)
I felt like he thought that was my civic duty to try and eliminate this disease, well if your baby’s 
got polycystic kidney disease, we’ll just terminate it and then you can try for another one, and 
there’s a 50% chance that it will or won’t, and you could just, terminate any defective ones. 
(Australia)
We cannot detect [ADPKD] before the end date of the abortion authorization. So, this is a debate 
that leads nowhere, because there is no opportunity to choose. It’s either we do not have 
children at all or we take the risk. (France)
Fetus is also a life. If a genetic test inds PKD, are you going to abort the fetus? No. So, if I ind 
out early with fetus in utero, I will feel guilty and have bad feelings. I just don’t see why this is 
necessary. (Korea)
Family pressure If they were planning on having children, I’d potentially encourage them to be tested before then 
just, so they can keep an extra eye on it. (Australia)
[PKD is] a family concern, because she’s my sister, she’s a bit concerned. So, she wants to 
make sure that the boys don’t have it. (Australia)
So, you know, my family’s all on my case, oh why don’t you get tested? (Australia)
You have to follow up. If someone is found in the family, who is affected, then … I got the report, 
you have to follow up on the rest of the family too … they are invited to do some research. 
(France)
Seizing control of well- being
Gaining conidence in early 
detection
If you know about it early, you can do some things to help yourself, to prolong [your kidneys] life. 
Maybe don’t have a huge steak and have more vegetables and less protein, lots of water and 
that sort of thing. (Australia)
Personally, I think that it must absolutely be done and know if one is sick or not to anticipate and 
preserve the maximum [kidney function]. (France)
I think it may be better to get children tested early. So that parents know, to better look after 
their health, their diet, care with sport… and then to tell them when they have grown up as 
adults to allow them to make informed decision. (Korea)
If you don’t know the result of genetic test, as a parent it is very dificult to reinforce the 
importance of dietary health, so as a parent there is deinitely an aspect you want to know 
(through genetic testing). (Korea)
Allowing preparation for the future I might’ve put more away in super rather than running my own business so much, had I known, 
but that opportunity wasn’t there for me because I didn’t know at that time. (Australia)
I went on dialysis a lot quicker because I was working in a job with huge stress. Now, if I would 
have known I would have got out of that job years before because I didn't realize that my blood 
pressure was like 180 over something. (Australia)
For someone who has gone on dialysis and sold my business and can't travel, if we had had 
been educated earlier, we would not have worked so hard, we would have had a holiday, all 
those things would have been done so we had no regrets later. (Australia)
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family members with ADPKD but were disappointed by a 
general lack of information.
Medicalising family planning
Some participants regretted having tests when they were 
advised against having children—‘[The doctors said] 
“don’t reproduce, that will stop the disease”’ (Australia). Some 
diagnosed through screening feared judgement from 
clinicians and felt pressured against having children. 
Others appreciated the direct advice in family planning 
to support their decision—‘[The doctors] told me “don’t do 
it”. And I made the choice—no kids’ (France). Some resisted 
prenatal testing to avoid having to confront decisions 
about termination of pregnancy—‘if genetic tests find PKD, 
are you going to abort the fetus? No. If I found out early with 
fetus in utero, I will feel guilty and have bad feelings’ (Korea). 
Some participants in France thought prenatal testing was 
useless because abortion was illegal—‘When he was in utero, 
I wanted to abort. At the time, it was not possible’ (France).
Family pressures
Some thought they should convince their family to get 
tested—‘From the moment I found that I had it, I wrote to all my 
relatives, and said, “Get screened”’ (Australia). Some parents 
expected that testing would motivate behaviour change to 
maintain health, and were frustrated when their child did 
not demonstrate effort to protect their kidney health—‘I 
keep nagging him to see a doctor, see a specialist, and he goes yeah, 
doctor said my kidneys are alright’ (Australia). For some, tests 
on children were a collective ‘family concern’ and decision.
Seizing control of well-being
Gaining conidence from early detection
An early diagnosis through testing was thought to provide 
an opportunity for participants to take control of their 
health by modifying their diet and taking preventive medi-
cations, such as antihypertensive agents. Participants were 
empowered to monitor their health vigilantly and gained 
confidence in their ability to preserve their QoL—‘Going 
Theme Illustrative quotations
Reassurance in family resilience This is generational, my mother’s father died of it. We’ve been quite used to it, if there’s such a 
thing as used to it, so our children, I don’t think would have a huge impact on them, they would 
know what to do. (Australia)
She was ine after testing, we discussed it, we had all sorts of chats about; what it’s going to be 
in the future and look at some of the other things you could have that would be far worse, and 
look on the bright side, at least you know about it and we can do preventative stuff. (Australia)
When we went and saw the genetic doctor the second time he gave us an actual formal letter 
and we passed it out throughout our kids, and mainly living cousins, so that if they wanted to go 
they could ring up and get an appointment, see him and get tested or whatever. (Australia)
PKD is hereditary in our family, I just think of it as a quirk, it’s just another thing that makes me 
different and unique so I’ve been very lucky to watch my grandmother and my father go through 
it and the way that they’ve approached it and dealt with it has given me hopefully a good 
attitude towards it, it doesn’t affect me yet so I am lucky, at this stage. (Australia)
Anticipating impact on quality of life
Reassured by lack of symptoms If you're getting towards 40, 50, 60 even and it hasn't bothered you until then, you're not going 
to be worried about it. (Australia)
‘Not until you're older.’ ‘Oh well, I suppose I'll worry about then.’ I wouldn't worry about it until I 
absolutely have to. (Australia)
I had children anyhow, even though I did know there was a risk. I was still healthy. I’ve got four 
lovely boys, two have got the disease. I do feel a bit of guilt about that for sure, but I wouldn’t 
give any of them back. (Australia)
I don’t think about it as I have not had any major problems related to the disease, but it’s true 
that I don’t have enough perspective to inform me. (France)
Judging the value of life with ADPKD You want your child to have the best life possible and be healthy and happy and everything like 
that but I don't see I’ve been ever denied anything or will ever be denied anything in life and if 
my parents had had the same decision would I exist today? (Australia)
I was fairly stubborn that I was never going to have children if I had PKD. I was 100% ixed in 
my head and nothing was going to change that but I decided I didn’t have PKD so it was all 
right, so I made that error now because I had the two most beautiful children and I really think 
you’ve got to be pretty careful in that area because you create beings that are adding quite a bit 
of value to society. (Australia)
My mother said a couple of times if she’d have known; she probably shouldn’t have had 
children. My take on that is I’ve had a really good 60 years with a bit of intervention, and she had 
three children without the kidney disease, so I was the only one of four. (Australia)
[My mother] said, ‘If I knew like you, you would not be here. Neither you nor your sister.’ I have 
no family. Because, I made the choice not to have children, but I made the right choice. (France)
ADPKD, autosomal dominant polycystic kidney disease; PKD, polycystic kidney disease.
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to the doctor regularly, just getting your blood pressure checked, 
because they say that if you can keep your blood pressure under 
control, they [kidneys] might not fail’ (Australia). For parents 
with a child with ADPKD, an early diagnosis motivated 
them to educate and ‘reinforce the importance of dietary 
health’ (Korea) in their children.
Allowing preparation for the future
An earlier diagnosis through testing enabled patients 
to mentally prepare for potential symptom burden and 
make lifestyle changes (including financial and career 
planning) to protect their QoL and avoid stress—‘Fore-
warned is forearmed’ (Australia). Some participants (partic-
ularly on dialysis) regretted not getting tested as they 
would have maximised their time while asymptomatic—‘If 
we had been educated earlier, we would not have worked so hard, 
we would have had a holiday, all those things would have been 
done so we had no regrets later’ (Australia).
Reassurance from family resilience
Some observed their parents’ optimism and resilience 
while on dialysis or with a transplant, and this strength-
ened confidence in their decision to be tested. Some 
appreciated that testing was more accessible for their 
children—‘now any of my family can go and get it done’ 
(Australia).
Anticipating impact on QoL
Reassured by lack of symptoms
Some participants were not interested in testing because their 
QoL had not been affected. They questioned ‘well do I actually 
have it’ and did not worry about their disease or testing—‘I 
have not had any major problems related to the disease’ (France). 
Some parents were not concerned with testing or genetic 
transmission as they believed their child would not suffer a 
disadvantaged life because they had not.
Judging the value of life with ADPKD
Some parents believed they would have decided against 
having children if they had been tested because ADPKD 
had caused their family to suffer—‘If I knew [that I had 
PKD], you would not be here’ (France). Some participants 
respected their parents’ decisions to have children but 
questioned that if they had had been tested ‘would I exist 
today?’ Some did not see the merit in testing as they valued 
their lives regardless of ADPKD—‘You’ve got to be pretty 
careful in that area because you create beings that are adding 
quite a bit of value to society’ (Australia).
DISCUSSION
For some patients with ADPKD and caregivers, testing 
provided an opportunity to gain certainty about their 
Figure 1 Thematic schema. Participants felt that their ability to take control of their health was inluenced by how prepared 
they were inancially and was hindered by the unpredictable nature of their disease symptoms (indicated by the solid lines). 
Participants often felt that they were conlicted in whether or not they wanted to be tested for polycystic kidney disease (PKD). 
This decisional uncertainty (indicated by the dotted lines) was prompted by the uncertainty in participant symptoms, whether 
they felt capable of seizing their health, how they anticipated the impact on PKD on the quality of their life and whether or not 
they had support and autonomy in their decisions. ADPKD, autosomal dominant polycystic kidney disease.
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health status, foster motivation and confidence for self- 
management, prepare mentally and financially for the 
onset of symptomatic disease and seek support from 
family. However, others perceived testing as futile because 
they perceived preventive measures had little impact, and 
the onset and course of ADPKD were unpredictable. They 
were also concerned about interpreting the results and 
the implications for their current and future life, which 
could cause unnecessary worry and anxiety, particularly 
with regard to family planning. The costs incurred in 
accessing testing and the potential financial discrimina-
tion they expected to endure would impose substantial 
constraints on their lives and futures.
Overall, the perspectives of patients and caregivers were 
similar as they felt inadequately equipped and conflicted 
in making decisions, which was exacerbated by a lack of 
support and information and perceived pressure from 
family and healthcare professionals. They were also uncer-
tain about the severity of the symptom burden, and it was 
difficult to judge the value of life with ADPKD. Patients 
who witnessed intense suffering in their family members 
with ADPKD were inclined to refuse testing to avoid 
becoming anxious about their future and did not expect 
that the diagnosis would increase their sense of control. 
Lack of support has been recognised and, through discus-
sions with specialists and patient advocates, this led to the 
development of a route map for ADPKD (available in 
three languages) intended to help patients and all stake-
holders navigate through the services available to them 
(including genetic testing, diagnostic, management and 
treatment options).18
The variability in policies across the countries and 
parent- child roles may also explain some differences in 
perspectives. The diagnosis of ADPKD using methods 
other than genetic testing is routinely offered as the latter 
is not readily available or accessible in many countries. 
The cost of testing was of particular concern to patients 
in Korea, which may reflect the fact that testing is not 
funded by the government.32
This has led to an increase in direct- to- consumer genetic 
testing, which has negative ramifications because the 
public is often unaware of their clinical and social impli-
cations.32 Korean patients were particularly concerned 
about the cost burden of the disease and expressed that 
they did not understand the added value of paying for 
a presymptomatic ultrasound test if cysts may develop 
later in life. A recent study showed that more than 70% 
of Korean patients believed that genetic testing should be 
included in Korea’s national health testing programme 
so these services can be provided at little expense.33 
In Australia, access to dialysis and transplantation is 
provided to all citizens via government- funded Medicare 
system.34 Transplantation is primarily limited due to insuf-
ficient kidney donors available to meet the number of 
potential recipients on the organ waiting list.34 Dialysis in 
Korea has also been covered since 1989 and this is similar 
in France.35 36 In France, genetic testing is not routinely 
offered to patients, although some could have free access 
to genetic testing (eg, if they were enrolled in the Genkyst 
observational cohort study37). In regard to legislative 
protection, Australia, France and Korea have compre-
hensive provisions pertaining to consent, autonomy and 
integrity of the person tested.38 In France, refusal of fetal 
testing for ADPKD may be due to fear of genetic trans-
mission and the illegality of termination of pregnancy 
after 12- week conception due to ADPKD.39 No partic-
ipants mentioned preimplantation genetic diagnosis, 
which highlights an information gap between countries. 
Variable perspectives can also be noted depending on the 
role of the participant regardless of their country of resi-
dence. In previous studies, parents have reported largely 
positive attitudes towards testing for children, while some 
children became more concerned about their health or 
the health of their family members.40 41 Younger patients 
expressed more anxiety around a diagnosis because they 
feared it could limit their future and were anxious about 
how quickly their health would decline.
Similar perspectives on testing have also been noted 
with other later onset progressive conditions including 
Huntington disease, characterised by a motor and cogni-
tive deterioration with unpredictable prognosis leading to 
similar decisional uncertainty in views about testing.42–44 
For patients with Huntington disease, family members 
could be perceived to have a supportive role or put pres-
sure on making decisions in terms of being presymp-
tomatically tested. They considered the consequences of 
sharing or withholding information about the diagnosis.45 
Some refused testing to avoid unnecessary anxiety before 
they experienced symptoms of the disease.45
Our findings are consistent with the concepts of multi-
generational transmission process in family system theory, 
which emphasises that an individual’s behaviour is inextri-
cably connected with the attitudes and behaviours learnt 
from their family.46 47 The multigenerational transmission 
process can help explain how decisions about testing 
can be shaped by observing the extent to which family 
members (particularly parents) suffered the symptoms of 
ADPKD.46 Some patients believed that their experience 
might be different from those of their family members 
and were uncertain about the chance of genetic transmis-
sion in family planning, while others were influenced by 
the adverse impact that ADPKD had on their family.
Our study spanned three countries and provided 
in- depth, diverse and novel insights about testing for 
ADPKD from a relatively large sample of patients and 
their caregivers purposively selected to include a range 
of demographic characteristics. We achieved data satura-
tion, coded the data in the language of the focus groups 
and used investigator triangulation in the analysis to 
ensure the themes reflected the breadth and depth of 
the data. However, there are some potential limitations. 
We are uncertain about the transferability of the findings 
to other countries with different healthcare policies on 
testing. We acknowledge that testing can be a sensitive 
topic and some views may have been suppressed in the 
focus group setting which may also explain why there was 
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limited variation in the perspectives of caregivers versus 
patients. We discussed testing for disease presence only in 
patients diagnosed with ADPKD and 31% were receiving 
kidney replacement therapy. We acknowledge that the 
findings may not include views of at- risk persons because 
of ethical reasons. Other limitations include the relatively 
low number of caregivers and other subgroups (ie, trans-
plant recipients) and being ethically unable to collect 
demographic characteristics from patients who declined 
to participate.
Our findings can inform ways to better inform and 
communicate with patients and their families. Knowledge 
of the available tests, prevention and management may 
support decision- making. Our findings support the value 
of genetic counsellors and education sessions prior to 
testing to help address the potential psychological and 
social consequences of testing to the individual and the 
family.45 Kidney Disease Improving Global Outcomes 
guidelines and the European ADPKD Forum suggest that 
patients with ADPKD should have access to reproductive 
counselling.29 48 However, as few as 20%–40% of nephrolo-
gists may actually inform their patients about the prenatal 
and preimplantation genetic diagnostic options due 
to ethical concerns while 68% of patients with ADPKD 
believe it should be offered.33 49 Clinicians have articu-
lated similar concerns about testing for ADPKD because 
of the perceived absence of curative treatment options 
and the perceived minimal burden on QoL. However, 
perceptions of testing may change with increasing avail-
ability and use of vasopressin receptor antagonists to 
prevent the progression of ADPKD.50 Ongoing clinical 
trials may provide additional options for treatment to 
slow progression.51–53 Concerns about discrimination 
in regard to disclosure of genetic status should also be 
addressed.54
For some patients with ADPKD, testing could empower 
them to take charge of their health while for others, 
receiving a confirmed diagnosis of ADPKD causes unnec-
essary anxiety over a disease that they limited control 
over. Testing positive for ADPKD could jeopardise 
employment opportunities for patients and complicate 
family planning and dynamics. Providing access to educa-
tion and genetic counselling in people at risk of ADPKD 
and their family, and psychosocial support after receiving 
the test results, are suggested to provide individuals with 
the capacity to make informed decisions and to empower 
them for self- management.
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Supplementary Material and Methods 
Supplementary Table 1. Question guide 
• What are your experiences (or thoughts) of genetic counselling/screening for ADPKD - in 
people who don't have symptoms but are at risk (i.e. because it is known to occur in the 
family)? 
• What advantages (kidney donation, family planning)/disadvantages (anxiety, 
financial/insurance, uncertainty of the future) do you think are important when/if you 
make decisions about genetic screening - why? 
• What about for children/family members? Do you think prenatal counselling would be 
useful/helpful? 
• What are some of the emotional, ethical/moral issues around genetic testing for ADPKD? 
 
Supplementary Table 2. Attendance in focus groups 
 
Group ID Country N 
1 Australia 9 
2 Australia 10 
3 Australia 6 
4 Australia 9 
5 Australia 10 
6 Australia 6 
7 Australia 8 
8 Australia 7 
9 Australia 7 
10 Australia 13 
11 France 6 
12 France 12 
13 France 11 
14 France 11 
15 Korea 12 
16 Korea 8 
17 Korea 9 
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